Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 20/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4038239 | 0.96 | KIF11 (0.76) | KIF11 | |
| SCHEMBL4036126 | 0.95 | KIF11 (0.74) | KIF11 | |
| SCHEMBL4039256 | 0.94 | KIF11 (0.73) | KIF11 | |
| SCHEMBL4036008 | 0.94 | KIF11 (0.73) | KIF11 | |
| SCHEMBL4037930 | 0.93 | KIF11 (0.71) | KIF11 | |
| SCHEMBL4039223 | 0.93 | KIF11 (0.71) | KIF11 | |
| SCHEMBL4037492 | 0.92 | KIF11 (0.71) | KIF11 | |
| SCHEMBL5899054 | 0.92 | KIF11 (0.70) | KIF11 | |
| SCHEMBL4038834 | 0.92 | KIF11 (0.70) | KIF11 | |
| SCHEMBL4038245 | 0.91 | KIF11 (0.84) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1601673-B1 | FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-06-10 | — | — | EP | claimed |
| US-7022850-B2 | Bicyclicpyrimidones and their use to treat diseases | BRISTOL-MYERS SQUIBB CO. (US) | 2006-04-04 | — | — | US | claimed |
| EP-1601673-B1 | FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-06-10 | — | — | EP | disclosed |
| US-7022850-B2 | Bicyclicpyrimidones and their use to treat diseases | BRISTOL-MYERS SQUIBB CO. (US) | 2006-04-04 | — | — | US | disclosed |
| EP-1628981-A2 | BICYCLICPYRIMIDONES AND THEIR USE TO TREAT DISEASES | Bristol-Myers Squibb Company (US) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004106492-A2 | BICYCLICPYRIMIDONES AND THEIR USE TO TREAT DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040242596-A1 | Bicyclicpyrimidones and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242596-A1 | Bicyclicpyrimidones and their use to treat diseases | CCNB1, CCNB2, CCNI | KIF11 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.